

# Aequus Pharmaceuticals Inc.

10:35 30 Nov 2020

## Aequus sees 3Q revenue jump double-digits year-over-year on increased market access and sales of PrVistitan and Tacrolimu

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) saw its revenue jump by double-digits year-over-year in the third quarter thanks to better market access and increased sales of its PrVistitan and Tacrolimu eye treatments.

The company posted revenue in the three months ended September 30, 2020, of C\$618,984, a 67% increase from the same quarter in 2019. Aequus also saw its 3Q net loss decrease to C\$251,921, down 62% year-over-year. The loss for the nine-month period to the same date was C\$879,984, a decrease of 57% year-over-year.

### READ: Aequus announces Anne Stevens is stepping down as chief operating officer

"We are very encouraged by our performance in the third quarter," said Aequus CEO Doug Janzen in the results statement. "We saw strong revenue growth from both PrVistitan and Tacrolimus and our losses were sharply reduced by 62% over the same period last year."

Janzen noted that the company received Health Canada approval for two Evolve-branded Dry Eye products as medical devices. He said they make up about 75% of the company's roughly C\$9 million peak revenue forecast for the Evolve line.

However, he said, Health Canada has informed the company that the 3rd Evolve product would not be approved as a medical device and should be resubmitted as an OTC (over-the-counter) product.

"We are confident that continued growth from our existing products and the Evolve launches will positively contribute to our bottom-line going forward into 2021," Janzen added.

Furthermore, the company said it has progressed discussions with potential buying groups active in eye care and expects its Aequus Eye Care E-Commerce platform will go live before the year-end.

Aequus also said it would continue leveraging its existing core capabilities and commercial infrastructure to expand its presence and product offerings within ophthalmology and optometry.

The company has positioned itself as a key partner for international companies looking to access the Canadian marketplace and will continue its strategy of adding to its existing product portfolio through promotional partnership agreements, asset acquisitions, and in-licenses.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

**Price:** 0.2

**Market Cap:** \$22.38 m

### 1 Year Share Price Graph



### Share Information

**Code:** AQS

**Listing:** TSX-V

**52 week High Low**  
0.275 0.065

**Sector:** Pharma & Biotech

**Website:** [www.aequuspharma.ca](http://www.aequuspharma.ca)

### Company Synopsis:

*Aequus Pharmaceuticals Inc. is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).